Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
0.0700
+0.0105 (17.65%)
NASDAQ · Last Trade: Aug 18th, 4:53 PM EDT
Detailed Quote
Previous Close
0.0595
Open
0.0878
Bid
0.0702
Ask
0.0708
Day's Range
0.0658 - 0.0884
52 Week Range
0.0593 - 1.330
Volume
499,428,190
Market Cap
107.50M
PE Ratio (TTM)
-0.6364
EPS (TTM)
-0.1
Dividend & Yield
N/A (N/A)
1 Month Average Volume
54,110,588
Chart
About Adaptimmune Therapeutics plc - American Depositary Shares (ADAP)
Adaptimmune is a biotechnology company focused on developing T-cell therapy to treat cancer. The company specializes in harnessing the power of the immune system, particularly using engineered T-cell receptors (TCRs), to target and eliminate cancer cells more effectively. Adaptimmune’s innovative approach aims to improve patient outcomes in various cancers by personalizing therapies to the individual’s unique tumor characteristics. Through ongoing research and clinical trials, the company strives to bring transformative treatment options to patients suffering from life-threatening malignancies. Read More
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Stay up-to-date with the latest market trends in the middle of the day on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
